Rizwan Nurani, MD
Radiation Oncology Physician in Apple Valley, California.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 6,029 in Radiation Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Rizwan Nurani, MD reported a CMS MIPS final score of 75/100 - below the 83.1 national average - and filed 422 Medicare Part D claims in 2023.
- 75/100
- MIPS score · -8 vs avg
- 422
- Part D claims, 2023
- 95%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Rizwan Nurani, MD's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure
75 15th percentile higher than 15% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Rizwan Nurani, MD sits
This provider among radiation oncology physician peers
Across the 1,988 radiation oncology physician providers who report both Medicare Part D prescribing and a MIPS quality score, Rizwan Nurani, MD writes more Part D claims than 95% of them and scores higher on MIPS quality than 12% - placing this provider in the high-volume, lower-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one radiation oncology physician peer from a representative sample of 60; the gold marker is Rizwan Nurani, MD. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
Rizwan Nurani, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Rizwan Nurani, MD?
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in California
How Radiation Oncology Physician compares to other specialties among California providers
Radiation Oncology Physician ranks #122 among California's specialties (0.1% of in-state providers)
Each bar is a specialty's share of the California provider total, by primary NUCC taxonomy. The highlighted bar is Radiation Oncology Physician; the long tail of smaller specialties is omitted for legibility.
Medicare quality performance, MIPS
Rizwan Nurani, MD's 2023 MIPS final score plotted against the Radiation Oncology Physician national average
- MIPS Final Score
- 75/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Radiation Oncology Physician) - 75/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Specialty volume Radiation Oncology Physician US NPIs
75/100 MIPS final score - 8.1 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Radiation Oncology Physician.
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Rizwan Nurani, MD appears in the CMS NPPES registry as a Radiation Oncology Physician provider holding MD credentials at 18092 WIKA RD STE 140, Apple Valley, CA, 92307, with a listed phone of (760) 503-5910. NPI 1386756245 was issued on 08/31/2006.
Medicare Part D records for calendar year 2023 show 422 prescription claims written by this provider, covering 201 Medicare beneficiaries and totaling roughly $32K in drug spend, split 5% brand-name and 95% generic by claim count. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 75/100 for the 2023 performance year, compared with the national average of 83.1.
Radiation Oncology Physician is a mid-sized specialty nationwide, with 6,029 enrolled providers across 53 states and an average of 186 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1386756245 |
|---|---|
| Specialty | Radiation Oncology Physician |
| Credentials | MD |
| Gender | Male |
| NPI Issued | 08/31/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm Rizwan Nurani, MD's current license status, disciplinary history, and board certifications with the Medical Board of California in California before relying on this page for a clinical or care decision.
How we sourced this profile
Profile fields combine the CMS NPPES monthly snapshot (provider directory, taxonomy, and address) with calendar-year 2023 Medicare Part D and MIPS public-use files when records are present. NPI 1386756245 is the unique 10-digit identifier CMS uses to link Nurani across every Medicare, Medicaid, and HIPAA-covered transaction. Read full methodology →
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Hospital and facility affiliations
Facilities where Rizwan Nurani, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Rizwan Nurani, MD. Source: openpaymentsdata.cms.gov.
Total received
$12.4K
Largest payer
Teleflex LLC
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - California MBC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 - they are NOT specific to Rizwan Nurani, MD. To verify Rizwan Nurani, MD's current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Generic-heavy
5% brand-name claims vs 95% generic, on 422 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 831
- Total Day Supply
- 22,199
- Brand vs Generic
- 5% brand / 95% generic
- Brand Drug Cost
- $17K
- Generic Drug Cost
- $15K
- Antibiotic Claims
- 80
Patient Demographics
- Average Patient Age
- 75.3 years
- Avg HCC Risk Score
- 1.45
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Rizwan Nurani, MD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Tamsulosin Hcl
Tamsulosin Hcl
165 claims
- Sulfamethoxazole-T… 58
Sulfamethoxazole-Trimethoprim
58 claims
- Bicalutamide 31
Bicalutamide
31 claims
- Myrbetriq 20
Myrbetriq
20 claims
- Oxybutynin Chlorid… 20
Oxybutynin Chloride Er
20 claims
- Ciprofloxacin Hcl 18
Ciprofloxacin Hcl
18 claims
- Dexamethasone 18
Dexamethasone
18 claims
- Sildenafil Citrate 16
Sildenafil Citrate
16 claims
| Drug | Claims |
|---|---|
| Tamsulosin Hcl | 165 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 58 |
| Bicalutamide | 31 |
| Myrbetriq Mirabegron | 20 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 20 |
| Ciprofloxacin Hcl | 18 |
| Dexamethasone | 18 |
| Sildenafil Citrate | 16 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Radiation Oncology Physician Overview
How Rizwan Nurani, MD fits within the Radiation Oncology Physician landscape nationally.
Rizwan Nurani, MD's 422 claims are above the specialty average of 186.
Nearby Radiation Oncology Physician Providers in California
Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as Nurani.
Compare Radiation Oncology Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the California medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Radiation Oncology Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore California
Frequently Asked Questions
What is Rizwan Nurani, MD's specialty? ▼
How much does Rizwan Nurani, MD prescribe under Medicare Part D? ▼
What is Rizwan Nurani, MD's Medicare quality score? ▼
Where is Rizwan Nurani, MD located? ▼
What is Rizwan Nurani, MD's NPI number? ▼
Does Rizwan Nurani, MD prescribe more brand-name or generic drugs? ▼
How many Radiation Oncology Physician providers are there in the US? ▼
What drugs does Rizwan Nurani, MD prescribe most often? ▼
Does Rizwan Nurani, MD accept Medicare? ▼
How can I verify Rizwan Nurani, MD's credentials? ▼
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.
Published by
PlainDoctor Editorial
Independent public-data reference that compiles, verifies, and contextualizes official datasets. We do not accept compensation from entities we cover, and every dataset cites its originating public source.